Untitled - Media Med Publicis

PROGRESE ÎN CARDIOLOGIE - Vol. III / 27
22. Elliott PM, Poloniecki J, Dickie S et al. Sudden death in hypertrophic cardiomyopathy:
identifi cation of high risk patients. J Am Coll Cardiol 2000; 7:2212-2218.
23. Menon SC, Bos M, Ommen SR, alti. Arrhythmogenic Malignances in Hypertrophic
Cardio myopathy. In: Gussak I, Antzelevitch C, editors. Electrical Diseases of the Heart.
London: Springer, 2008: 610-626.
24. Maron BJ, Spirito P, Shen WK et al. Implantable Cardioverter-Defi brillators and Prevention
of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JAMA: The Journal of
the American Medical Association 2007; 298(4):405-412.
25. Lee KL, Tse H-F, Lau C-P. Structural heart disease, syncope, and risk of sudden death:
selection of patients for implantable cardioverter-defi brillator therapy. In: Benditt DG,
Brignole M, Raviele A, Wouter W, editors. Syncope and Transient Loss of Consciouseness.
Oxford: Blackwell Futura, 2007: 89-94.
26. Boussy T, Brugada P. Channelopathies as a cause of syncope. In: Benditt DG, Brignole
M, Raviele A, Wouter W, editors. Syncope and Transient Loss of Consciouseness.
Oxford: Blackwell Futura, 2007: 95-101.
27. Priori SG, Barhanin J, Hauer RN et al. Genetic and molecular basis of cardiac arrhythmias:
impact on clinical management. Circulation 1999; 99:518-528.
28. Moss AJ, Kass RS. Long QT syndrome: from channels to cardiac arrhythmias. J Clin
Invest 2005; 115:2018-2024.
29. Antzelevitch C, Burashnikov A. Mechanisms of arrhythmogensis. In: Podrid PJ, Kowey
PR, editors. Cardiac Arrhythmia: Mechanisms, Diagnosis and Managemet. Philadelphia:
Lippincott Williams & Wilkins, 2001: 51-79.
30. Camm AJ, Janse MJ, Roden DM et al. Congenital and acquired long QT syndrome. Eur
Heart J 2000; 21:1232-1237.
31. Kass RS, Moss AJ. Long QT syndrome: novel insights into the mechanisms of cardiac
arrhyth mias. J Clin Invest 2003; 112:810-815.
32. Roden DM, Viswanathan PC. Genetic of acquired long QT syndrome. J Clin Invest
2005; 115:2025-2032.
33. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000;
84:339-346.
34. Viskin S, Rosovski U, Sands AJ et al. Inaccurate electrocardiographic interpretation of
long QT: The majority of physicians cannot recognize a long QT when they see one.
Heart Rhythm 2005; 2:569-574.
35. Ackerman MJ, Kositseth A, Tester DJ, et al. Congenital Long QT Syndrome. In: Gussak
I, Antzelevitch C, editors. Electrical Diseases of the Heart. London: Springer, 2008:
462-482.
36. Zareba W, Moss AJ, Schwartz PJ et al. Infl uence of the Genotype on the Clinical Course
of the Long-QT Syndrome. N Engl J Med 1998; 339(14):960-965.
37. Moss AJ, Zareba W, Hall WJ et al. Effectiveness and Limitations of Beta-Blocker Therapy
in Congenital Long-QT Syndrome. Circulation 2000; 101(6):616-623.
38. Antzelevitch C, Viskin S. Brugada Syndrome: Cellular Mechanism and Approaces to
Thera py. In: Gussak I, Antzelevitch C, editors. Electrical Diseases of the Heart. London:
Springer, 2008: 500-535.
39. Antzelevitch C, Brugada P, Borggrefe M et al. Brugada Syndrome: Report of the Second
Con sensus Conference. Circulation 2005; 111(5):659-670.
40. Gaita F, Giustetto C, Bianchi F et al. Short QT Syndrome: A Familial Cause of Sudden
Death. Circulation 2003; 108(8):965-970.
41. Priori SG, Napolitano C, Memmi M et al. Clinical and Molecular Characterization
of Pa tients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation
2002; 106(1):69-74.